Pisa, Italy

Claudia Martini

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2012-2019

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Claudia Martini: Innovator in Pharmaceutical Research

Introduction

Claudia Martini is a prominent inventor based in Pisa, Italy. She has made significant contributions to the field of pharmaceutical research, particularly in the development of compounds that target critical enzymes involved in various diseases. With a total of 2 patents, her work has the potential to impact the treatment of serious health conditions.

Latest Patents

Martini's latest patents include innovative compounds such as 2-oxo-1,2-dihydropyridine-3-carboxamide. This compound is designed to act as an inhibitor of the PDK1 enzyme, which is crucial in the treatment of pathologies like diabetes, neurodegenerative diseases such as Alzheimer's and Prion Diseases, as well as tumors including breast and pancreatic cancers, particularly glioblastoma. Another notable patent involves GPR17 modulators, which provide methods for screening and therapeutic uses in diagnosing diseases related to GPR17 activation, especially ischemic brain damage.

Career Highlights

Throughout her career, Claudia Martini has worked at esteemed institutions such as the University of Milan and the University of Pisa. Her research has focused on developing novel therapeutic strategies that address significant health challenges.

Collaborations

Martini has collaborated with notable colleagues in her field, including Maria Pia Abbracchio and Paolo Ciana. These partnerships have enhanced her research and contributed to the advancement of pharmaceutical sciences.

Conclusion

Claudia Martini's innovative work in pharmaceutical research exemplifies her commitment to addressing critical health issues through her inventions. Her contributions are paving the way for new treatments that could significantly improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…